GMO Equity Dislocation

In late 2020, we launched GMO’s Equity Dislocation Strategy to exploit the extraordinary dislocation in the valuation of value and growth stocks. We sought to generate strong returns from the bursting of the growth bubble and narrowing of valuations between the cheapest and most expensive stocks. From its inception in October 2020 through January 2024, Equity Dislocation returned 13.5% per annum 1 while MSCI ACWI Value only beat MSCI ACWI Growth by a modest 4.1% per annum. Equity Dislocation significantly outperformed a passive value-growth implementation due a combination of strong stock selection, a focus on the most mispriced securities, and thoughtful risk controls.

equity dislocation

The Opportunity Today

Despite solid returns to date, we believe the opportunity for Equity Dislocation remains compelling. The chart below shows the valuation of the cheap 50% of the U.S. market relative to the expensive 50% of the U.S. market, normalized such that 1.0 is the historic median. As of January 31, 2024, the U.S. valuation differential between value and growth remains at a historic extreme (4th percentile vs. history) due to the significant outperformance of growth stocks in 2023. In Europe, the opportunity is similarly attractive at the 2nd percentile vs. history. 2 Valuation spreads within sectors remain dislocated with the ratio of the most expensive vs. cheapest valuation terciles in the top quartile across nearly all sectors relative to history (Energy and Real Estate are the exception, near average). 3

All together, we estimate that value globally still needs to outperform growth by 50-60% for relative valuations to return to long-term averages. Consequently, Equity Dislocation remains the largest single exposure in our Benchmark-Free Allocation Strategy.